Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
Authors:
Top Cited Papers
Open Access
- 15 June 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Review of Economic Studies
- Vol. 86 (1) , 117-152
Abstract
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our article makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant expenditures to private-sector innovations. Second, we take advantage of idiosyncratic rigidities in the rules governing NIH peer review to generate exogenous variation in funding across research areas. Our results show that NIH funding spurs the development of private-sector patents: a $10 million boost in NIH funding leads to a net increase of 2.7 patents. Though valuing patents is difficult, we report a range of estimates for the private value of these patents using different approaches.Keywords
This publication has 74 references indexed in Scilit:
- Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical PatentsPLOS ONE, 2012
- The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industryResearch Policy, 2012
- The impact of research grant funding on scientific productivityJournal of Public Economics, 2011
- Funding of US Biomedical Research, 2003-2008JAMA, 2010
- The Value of Specialty Oncology DrugsHealth Services Research, 2010
- NIH funding trajectories and their correlations with US health dynamics from 1950 to 2004Proceedings of the National Academy of Sciences, 2009
- Treatment for chronic myelogenous leukemia: the long road to imatinibJournal of Clinical Investigation, 2007
- Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting, 1965–1988Review of Economics and Statistics, 1998
- Public–private interaction in pharmaceutical researchProceedings of the National Academy of Sciences, 1996
- The Evolution of Integrative Capability: Innovation in Cardiovascular Drug DiscoveryIndustrial and Corporate Change, 1994